Retatrutide and GHK-Cu stack claims: what the science says
Quick answer
Retatrutide, a triple incretin receptor agonist in clinical trials, shares a drug class with GLP-1 agonists that have been associated with telogen effluvium, likely secondary to rapid weight loss rather than direct follicle toxicity. GHK-Cu (copper tripeptide-1) has in vitro and limited in vivo evidence supporting hair follicle stimulation, but no published clinical trial has tested it as a protective agent against GLP-1-associated hair shedding. The creator's subjective report of hair regrowth while stacking both compounds cannot distinguish drug effect from individual variation or placebo response.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @filmedwithvictoria actually say?
She said she cannot answer whether retatrutide causes hair loss because she is not using it alone. She is stacking it with GHK-Cu (which she calls "GHQ") and attributed her lack of hair shedding and visible baby hair regrowth to that combination. Her exact position: "I don't know the answer to that if you're just on reda maybe, but personally I have not experienced any crazy hair loss shedding." She credits the GHK-Cu for the protective effect.
To her credit, she did not claim retatrutide definitively causes or prevents hair loss. She framed this as personal anecdote, not clinical guidance. That level of epistemic humility is rare on TikTok. But the leap from "I have baby hairs" to "stacking protects you" is where things get shaky.
Does the science back this up?
The short answer: GHK-Cu has real but modest evidence for hair support, while retatrutide's hair loss link is plausible but not yet well-characterized in published data. The stack claim, however, has no clinical evidence behind it at all.
GHK-Cu (copper tripeptide-1) has been studied in the context of hair follicle biology. Uno et al. (1987, Journal of Investigative Dermatology) showed copper peptides could stimulate follicle size in animal models. Pickart et al. (2015, Journal of Aging Science) reviewed GHK's role in tissue remodeling, including hair follicle signaling. These are real findings, but they come from in vitro and animal studies, or small human trials. No large randomized controlled trial has confirmed that GHK-Cu reverses drug-induced hair shedding in humans.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Hair shedding (telogen effluvium) is a known side effect class for GLP-1 receptor agonists, likely tied to rapid weight loss causing nutritional stress on hair follicles. Etminan et al. (2024, JAMA Dermatology) found a statistically significant association between GLP-1 agonist use and alopecia reports in a pharmacovigilance analysis. Retatrutide-specific hair data from Phase 2 trials (Jastreboff et al., 2023, NEJM) did not break out hair loss as a primary endpoint.
What did they get wrong (or right)?
She got the uncertainty right. Saying "I don't know" is honest, and the hair loss question for retatrutide specifically is genuinely unresolved in published literature. That is accurate.
What she got wrong, or at least overreached on, is the implied mechanism. Saying "probably because of the GHQ" treats a personal anecdote as a controlled observation. She has no baseline, no control arm, and no way to know whether she would have lost hair on retatrutide alone. It is possible she simply does not have the genetic predisposition that makes GLP-1-associated telogen effluvium likely. Individual variation is a real factor.
The "skin glow" attribution to the stack is similarly unverifiable. GHK-Cu does have collagen synthesis and antioxidant signaling support in the literature (Pickart and Margolina, 2018, Biomedicines), but attributing visible skin changes to a peptide stack based on appearance in a TikTok video is not a meaningful data point.
She also never clarifies what "GHQ" is by its full name. For viewers unfamiliar with peptide shorthand, this creates confusion. Unbranded compound stacks discussed in public health-adjacent content should be named clearly.
What should you actually know?
If you are on a GLP-1 class drug and worried about hair loss, the most likely driver is telogen effluvium from rapid weight loss, not a direct follicle toxicity from the drug itself. Stabilizing weight loss rate, maintaining adequate protein intake, and monitoring micronutrients like zinc, iron, and biotin are approaches with more clinical support than adding a topical or injectable peptide to your stack.
GHK-Cu has a reasonable safety profile and some legitimate science behind it for skin and hair biology. But "I have baby hairs while using both" is not evidence that GHK-Cu blocked retatrutide-related shedding. Correlation in a single user is not causation, and anyone making treatment decisions based on this video should understand that gap clearly.
Retatrutide is not FDA-approved as of mid-2025. Any access is through compounded formulations, which are not equivalent to a brand-name approved product. If you are considering this drug for any reason, that conversation belongs with a licensed provider who can review your full medical history, not a TikTok comment section.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
GHK-Cu (Copper Peptide) access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 11 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Retatrutide and GHK-Cu stack claims: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GHK-Cu (Copper Peptide) is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this ghk-cu video claims cluster
Best for searchers checking whether GHK-Cu beauty and recovery claims match the evidence base.
Claim verdict
The useful answer behind this video
Claim being checked
Retatrutide, a triple incretin receptor agonist in clinical trials, shares a drug class with GLP-1 agonists that have been associated with telogen effluvium, likely secondary to rapid weight loss rather than direct follicle toxicity.
FormBlends verdict
Retatrutide, a triple incretin receptor agonist in clinical trials, shares a drug class with GLP-1 agonists that have been associated with telogen effluvium, likely secondary to rapid weight loss rather than direct follicle toxicity. GHK-Cu (copper tripeptide-1) has in vitro and limited in vivo evidence supporting hair follicle stimulation, but no published clinical trial has tested it as a protective agent against GLP-1-associated hair shedding. The creator's subjective report of hair regrowth while stacking both compounds cannot distinguish drug effect from individual variation or placebo response.
Patient-safe next step
Compare the claim with the GHK-Cu (Copper Peptide) guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Retatrutide, a triple incretin receptor agonist in clinical trials, shares a drug class with GLP-1 agonists that have been associated with telogen effluvium, likely secondary to rapid weight loss rather than direct follicle toxicity. GHK-Cu (copper tripeptide-1) has in vitro and limited in vivo evidence supporting hair follicle stimulation, but no published clinical trial has tested it as a protective agent against GLP-1-associated hair shedding. The creator's subjective report of hair regrowth while stacking both compounds cannot distinguish drug effect from individual variation or placebo response.
- Telogen effluvium associated with GLP-1 receptor agonists is likely driven by rapid caloric deficit and weight loss stress on hair follicles, not direct drug toxicity, based on current pharmacological understanding.
- Etminan et al. (2024, JAMA Dermatology) found a statistically significant association between GLP-1 agonist use and alopecia in a large pharmacovigilance analysis, though retatrutide-specific hair data remains limited.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- GHK-Cu (Copper Peptide) decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the GHK-Cu (Copper Peptide) guide, cost path, safety notes, and provider review before acting.
Review GHK-Cu (Copper Peptide)What You'll Learn
- Telogen effluvium associated with GLP-1 receptor agonists is likely driven by rapid caloric deficit and weight loss stress on hair follicles, not direct drug toxicity, based on current pharmacological understanding.
- Etminan et al. (2024, JAMA Dermatology) found a statistically significant association between GLP-1 agonist use and alopecia in a large pharmacovigilance analysis, though retatrutide-specific hair data remains limited.
- GHK-Cu (copper tripeptide-1) has follicle-stimulating evidence in animal models and small studies (Uno et al., 1987, Journal of Investigative Dermatology), but no published trial tests it as a protective agent against drug-induced hair shedding.
- Retatrutide is not FDA-approved as of mid-2025. Compounded versions are not equivalent to any approved brand-name drug and are subject to supply and quality variability.
- One person's anecdotal stack experience cannot control for genetic variation in hair loss susceptibility, weight loss rate, protein intake, or micronutrient status, all of which independently influence telogen effluvium risk.
- If hair shedding occurs during GLP-1 class therapy, evidence-supported steps include slowing weight loss rate, ensuring adequate dietary protein, and checking ferritin and zinc levels before adding unproven peptide interventions.
- The creator's admission that she cannot answer the question for retatrutide alone is honest and scientifically appropriate. The follow-up claim that stacking solves the problem is not supported by evidence.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Victoria Senger · TikTok creator
4.5K views on this video
I love the Reta ghkcu stack personally 🫶🏻 #peptideskincare
Sources & references
- [1]Uno et al. (1987)
- [2]Pickart et al. (2015)
- [3]Etminan et al. (2024)
- [4]Jastreboff et al., 2023
- [5]Pickart and Margolina, 2018
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Victoria Senger, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.